February 17, 2022Open Access

Long‐term, durable, absolute Psoriasis Area and Severity Index and health‐related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate‐to‐severe plaque psoriasis

MGMelinda GooderhamQueen's University APAndreas PinterGoethe University Frankfurt LFLaura K. FerrisUniversity of North Carolina at Chapel Hill

Key Points

Key points are not available for this paper at this time.

Abstract

Risankizumab treatment demonstrated high rates of rapid and durable efficacy as measured by absolute PASI thresholds and improvements in patient HRQoL.

AIに質問

Bookmark

View Full Paper